Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma
This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ003 in the treatment of advanced hepatocellular carcinoma.
Advanced Hepatocellular Carcinoma
BIOLOGICAL: SZ003 CAR-NK
The incidence rates and severity of AEs, To evaluate the safety of SZ003 CAR-NK Cells, through study completion, an average of 1 year
overall survival (OS), To determine the anti-tumor effectivity of SZ003 CAR-NK Cells, up to 2 years|progression-free survival (PFS), To determine the anti-tumor effectivity of SZ003 CAR-NK Cells, up to 2 years|disease control rate (DCR) and objective response rate (ORR), To determine the anti-tumor effectivity of SZ003 CAR-NK Cells, up to 2 years|duration of response (DOR), To determine the anti-tumor effectivity of SZ003 CAR-NK Cells, up to 2 years
This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ003 in the treatment of advanced hepatocellular carcinoma.